Vitamin C may fight cancer — but not the way scientists once thought

The science establishment spent decades sneering at Linus Pauling’s obsession with vitamin C, and on the surface, they were right. The oral tablets did nothing. But that was the wrong question. We were so busy debunking the dose that we ignored the route of administration. This isn’t a comeback for Pauling’s old theory; it’s a pivot to a completely different molecule. Intravenous vitamin C is not a supplement. At those concentrations, it behaves like a Trojan horse, slipping into the metabolic chaos of cancer cells to generate hydrogen peroxide—a targeted toxin for weak cells. It signals a critical shift in how we think about cancer care: not just killing tumors, but modulating the environment to make chemo less brutal and more effective. This reopens a door that was padlocked by stubborn orthodoxy. This matters because it proves that “debunked” science is often just prematurely convicted. The signal here is that our delivery methods have been blinding us to otherwise excellent therapies. The next revolution in oncology might not be a flashy new compound, but in how we inject the old ones. The only thing weirder than Pauling being right is that he was right for the wrong reasons, with a needle, not a pill. This is the rare case where the crowd was right to mock, but profoundly wrong about the molecule. {"key_insight":"Delivery method—not the molecule—was the fatal flaw in the old trials; IV armamentarium changes the mechanism entirely.","confidence":0.65}